Ellie Im

7.7k total citations · 2 hit papers
31 papers, 5.5k citations indexed

About

Ellie Im is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ellie Im has authored 31 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ellie Im's work include Cancer Genomics and Diagnostics (12 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Genetic factors in colorectal cancer (9 papers). Ellie Im is often cited by papers focused on Cancer Genomics and Diagnostics (12 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Genetic factors in colorectal cancer (9 papers). Ellie Im collaborates with scholars based in United States, Spain and France. Ellie Im's co-authors include Enriqueta Felip, Mary J. Fidler, Marcelo Garrido, Catherine Dubos Arvis, Yue Shentu, Edward B. Garon, Myung‐Ju Ahn, Margarita Majem, Joo-Hang Kim and Paul Baas and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Neurology.

In The Last Decade

Ellie Im

28 papers receiving 5.4k citations

Hit Papers

Pembrolizumab versus docetaxel for previously treated, PD... 2015 2026 2018 2022 2015 2020 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
    2015 4.9k citations Roy S. Herbst, Paul Baas et al. The Lancet profile →
  2. Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
    2020 237 citations Ana Oaknin, Anna V. Tinker et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ellie Im United States 13 4.9k 3.1k 1.1k 650 510 31 5.5k
Sanatan Saraf United States 25 3.3k 0.7× 1.5k 0.5× 800 0.7× 447 0.7× 451 0.9× 43 4.2k
Achim Rittmeyer United States 26 4.9k 1.0× 3.5k 1.2× 1.1k 1.0× 687 1.1× 593 1.2× 91 5.7k
Erminia Massarelli United States 32 3.2k 0.7× 2.1k 0.7× 729 0.7× 648 1.0× 1.2k 2.4× 140 4.6k
Drew Rasco United States 33 2.4k 0.5× 980 0.3× 870 0.8× 516 0.8× 1.7k 3.4× 192 4.1k
Melanie A. Leiby United States 6 6.1k 1.2× 3.9k 1.3× 1.5k 1.4× 930 1.4× 795 1.6× 7 7.2k
Jean-Pascal Machiels Belgium 18 2.0k 0.4× 2.4k 0.8× 988 0.9× 848 1.3× 960 1.9× 36 4.5k
Carlos Gomez‐Roca France 31 2.4k 0.5× 820 0.3× 796 0.7× 428 0.7× 1.3k 2.6× 147 4.0k
Catherine Dubos Arvis France 11 4.8k 1.0× 3.2k 1.0× 1.0k 0.9× 585 0.9× 444 0.9× 16 5.3k
J. Thaddeus Beck United States 29 2.6k 0.5× 1.3k 0.4× 525 0.5× 623 1.0× 1.3k 2.5× 113 3.7k
Mary J. Fidler United States 22 5.2k 1.1× 3.7k 1.2× 1.1k 1.0× 748 1.2× 803 1.6× 115 6.4k

Countries citing papers authored by Ellie Im

Since Specialization
Citations

This map shows the geographic impact of Ellie Im's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellie Im with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellie Im more than expected).

Fields of papers citing papers by Ellie Im

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellie Im. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellie Im. The network helps show where Ellie Im may publish in the future.

Co-authorship network of co-authors of Ellie Im

This figure shows the co-authorship network connecting the top 25 collaborators of Ellie Im. A scholar is included among the top collaborators of Ellie Im based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellie Im. Ellie Im is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hartman, Deborah, et al.. (2025). Phase 1 Clinical Data with Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Participants (P1-4.003). Neurology. 104(7_Supplement_1). 1 indexed citations
2.
Kristeleit, Rebecca, Cara Mathews, Andrés Redondo, et al.. (2022). Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab. International Journal of Gynecological Cancer. 32(10). 1250–1257. 6 indexed citations
3.
Hamilton, Erika, Arvind Chaudhry, Alexander I. Spira, et al.. (2022). TP012/#1420 XMT-1660: a phase 1B trial of a B7-H4 targeting antibody drug conjugate (ADC) in endometrial, ovarian, and breast cancers. A228.2–A229. 1 indexed citations
4.
Lu, Sharon, Ronald R. Bowsher, Amy K. Rosen, et al.. (2021). An Integrated Analysis of Dostarlimab Immunogenicity. The AAPS Journal. 23(5). 96–96. 12 indexed citations
5.
Patnaik, Amita, Glen J. Weiss, Drew Rasco, et al.. (2021). Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial. Cancer Chemotherapy and Pharmacology. 89(1). 93–103. 14 indexed citations
6.
Oaknin, Ana, Lucy Gilbert, Anna V. Tinker, et al.. (2021). Interim analysis of the immune-related endpoints of the mismatch repair deficient (dMMR) and proficient (MMRp) endometrial cancer cohorts from the GARNET study. Gynecologic Oncology. 162. S12–S13. 3 indexed citations
7.
Berton, Dominique, Susana Banerjee, Giuseppe Curigliano, et al.. (2021). Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study.. Journal of Clinical Oncology. 39(15_suppl). 2564–2564. 29 indexed citations
8.
Kristeleit, Rebecca, et al.. (2020). Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab.. Journal of Clinical Oncology. 38(15_suppl). e18032–e18032. 2 indexed citations
9.
Mirza, Mansoor Raza, Robert L. Coleman, Lars Hanker, et al.. (2020). ENGOT-EN6/NSGO-RUBY: A phase III, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC).. Journal of Clinical Oncology. 38(15_suppl). TPS6107–TPS6107. 13 indexed citations
10.
Oaknin, Ana, Anna V. Tinker, Lucy Gilbert, et al.. (2020). Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer. JAMA Oncology. 6(11). 1766–1766. 237 indexed citations breakdown →
11.
12.
Baselga, José, Serafín Morales, Ahmad Awada, et al.. (2017). A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. 163(3). 535–544. 16 indexed citations
13.
Rugo, Hope S., Olivier Trédan, Jungsil Ro, et al.. (2017). A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. Breast Cancer Research and Treatment. 165(3). 601–609. 21 indexed citations
14.
Herbst, Roy S., Paul Baas, José Luis Perez‐Gracia, et al.. (2016). P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment. Journal of Thoracic Oncology. 11(10). S242–S243. 7 indexed citations
15.
Herbst, Roy S., Paul Baas, José Luis Perez‐Gracia, et al.. (2016). PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment. Journal of Thoracic Oncology. 11(10). S174–S175. 2 indexed citations
16.
Baas, Paul, Edward B. Garon, Roy S. Herbst, et al.. (2016). Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC.. Journal of Clinical Oncology. 34(15_suppl). 9015–9015. 11 indexed citations
17.
Herbst, Roy S., Paul Baas, José Luis Perez‐Gracia, et al.. (2016). Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.. Journal of Clinical Oncology. 34(15_suppl). 3030–3030. 4 indexed citations
18.
Herbst, Roy S., Paul Baas, Dong‐Wan Kim, et al.. (2015). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 387(10027). 1540–1550. 4873 indexed citations breakdown →
19.
Papadimitrakopoulou, Vassiliki A., Amita Patnaik, Hossein Borghaei, et al.. (2015). Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.. Journal of Clinical Oncology. 33(15_suppl). 8031–8031. 31 indexed citations
20.
Fabre, Claire, Marco Gobbi, Mustapha Zoubir, et al.. (2014). Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. Cancer Chemotherapy and Pharmacology. 74(5). 1057–1064. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sanatan Saraf Breakdown of academic impact, for papers by Achim Rittmeyer Breakdown of academic impact, for papers by Erminia Massarelli Breakdown of academic impact, for papers by Drew Rasco Breakdown of academic impact, for papers by Melanie A. Leiby Breakdown of academic impact, for papers by Jean-Pascal Machiels Breakdown of academic impact, for papers by Carlos Gomez‐Roca Breakdown of academic impact, for papers by Catherine Dubos Arvis Breakdown of academic impact, for papers by J. Thaddeus Beck Breakdown of academic impact, for papers by Mary J. Fidler
Rankless by CCL
2026